greenwhey-peptide-collagenegreenwhey-peptide-collagene October 2025 is shaping up to be a significant month for peptide news, with ongoing advancements in drug delivery, manufacturing, and therapeutic applicationsInnovative chemical tools for the synthesis of disulfide-rich peptides, an emerging class of medium-sized pharmaceuticals.. The field of peptide research and development continues its rapid expansion, moving from niche scientific interest into mainstream therapeutic considerations. This month's developments highlight collaborations aimed at improving oral peptide drug delivery, significant investments in manufacturing capabilities, and evolving regulatory discussions surrounding peptide therapies, particularly in areas like obesity and diabetes management.
The landscape of peptide therapeutics is being actively shaped by strategic partnerships and technological innovations. BioMed X and Novo Nordisk have launched a new collaboration focused on oral peptide drug delivery, signaling a drive to overcome traditional injection barriers. This initiative aligns with broader trends in peptide drug development, where enhanced bioavailability and patient convenience are key objectives.SK pharmteco Boosts Domestic Peptide Scale-Up with ...
In parallel, Lifecore and PolyPeptide have announced a collaboration intended to offer end-to-end peptide manufacturing solutions for the U.S. market, set to commence in October 2025.2天前—Experts described what was happening as “extremely dangerous”, warning that digital marketing techniques were being applied to pharmaceuticals ... This development underscores the growing demand for robust peptide manufacturing infrastructure to support the increasing pipeline of peptide-based drugs. SK pharmteco is also bolstering its domestic peptide scale-up capabilities with significant investments in its California facility, leveraging proprietary chromatography expertise作者：F Celletti·被引用次数：9—As ofOctober 2025, 12 GLP-1 therapies have been approved for indications in type 2 diabetes and/or obesity, while over 40 agents—including .... These manufacturing advancements are crucial for meeting the projected growth in peptide therapeutics.
October 2025 also sees continued focus on specific therapeutic areas where peptides are making a substantial impact. The WHO guideline on GLP-1 therapies for obesity in adults reflects the growing recognition of these peptide-based treatments. As of October 2025, numerous GLP-1 therapies are approved for type 2 diabetes and obesity, with many more agents in development. This surge in GLP-1 treatments has also seen a significant increase in their dispensing, with data showing hundreds of thousands of items dispensed for conditions like type 2 diabetes and obesity.
Beyond metabolic disorders, research is exploring novel applications. For instance, the enzyme PapB shows potential to boost diabetes and obesity peptide drugs, indicating a search for synergistic approaches.Peptide vaccines - Latest research and news Furthermore, advancements in deep learning are unlocking new possibilities, such as the development of antimicrobial self-assembling peptides, showcasing the power of artificial intelligence in peptide discovery.
The peptide industry's dynamism is further evidenced by a series of upcoming events3天前—The expert says the drugs can be dangerous and many are sold based on unproven claims.. The Peptide Therapeutics Symposium is scheduled for October 21-22, 2025, offering a hybrid format for researchers and industry professionals to discuss the latest breakthroughs. Similarly, the Japanese Peptide Symposium is set to take place from October 21-23, 2025, highlighting global engagement in peptide sciencePeptides news - the latest biotech ....
As peptide therapies move from fringe to mainstream, regulatory discussions are becoming increasingly important.Lifecore and PolyPeptide Announce CollaborationIntended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market. 28 October 2025. The year 2025 has seen peptide therapy gain significant traction online, particularly among biohackers, leading to increased scrutiny and a lag in regulation for some applications. This evolving regulatory environment, coupled with the growing market for peptide therapeutics, presents both opportunities and challenges for the industry.
The developments in October 2025 paint a picture of a maturing and rapidly expanding peptide sector. With ongoing innovations in drug delivery, manufacturing capacity expansion, and a broadening range of therapeutic applications, peptides are solidifying their role as vital components of modern medicine. The convergence of advanced research, strategic industry collaborations, and evolving market dynamics suggests a continued trajectory of growth and impact for peptide-based solutions in the coming years.
Join the newsletter to receive news, updates, new products and freebies in your inbox.